Table 3.
Randomized trials with terbinafine 250 mg daily
| Trial design | Subject (n) | Treatment duration | Mycological cure rate at study end | Reference | |
|---|---|---|---|---|---|
| Terbinafine 250 mg daily vs placebo | Terbinafine | Placebo | |||
| 112 | 3 months | 48% | 13% | Goodfield et al 1992 | |
| 111 | 3 months | 59% | 9% | Watson et al 1995 | |
| 358 | 3 and 6 months | 70% and 87% | 9% | Drake et al 1997 | |
| Terbinafine 250 mg daily vs itraconazole 200 mg daily | Terbinafine | Itraconazole | |||
| 195 | 3 months | 78% | 61% | Brautigam et al 1995 | |
| 372 | 3 months | 73% | 46% | De Backer et al 1998 | |
| Continuous terbinafine 250 mg daily vs intermittent itraconazole 400 mg daily (LION Study) | Terbinafine | Itraconazole | |||
| 496 | Terbinafine daily for 3 or 4 months, or itraconazole 1 week in every 4, for 3 or 4 months | 76% (3 months) and 81% (4 months) | 38% (3 months) and 49% (4 months) | Evans and Sigurgeirsson 1999 | |
| Terbinafine vs griseofulvin | Terbinafine | Griseofulvin | |||
| 195 | 24 weeks terbinafine vs 24 weeks griseofulvin | 81% | 62% | Hofmann et al 1995 | |
| 180 | 12 weeks | 90% | 64% | Haneke et al 1995 | |
| Terbinafine 250 mg daily vs fluconazole 150 mg daily | Terbinafine | Fluconazole | |||
| 137 | 3 months terbinafine vs 3 or 6 months fluconazole | 88% | 51% (3 months) 49% (6 months) | Havu et al 2000 |
Abbreviations: LION, lamisil vs itraconazole in onychomycosis.